Douglas Pharmaceuticals Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Douglas Pharmaceuticals Limited
Four years after Pfizer acquired Icagen for $56m, the big pharma sold the drug discovery firm to XRpro Sciences for up to $11m, which would seem to be a big discount if the deal gave the buyer access to compounds generated by Icagen's ion channel biology platform.
The FDA on 1 April unveiled its final guidance advising makers of brand-name opioids about what they need to do to obtain abuse-deterrent language in the labeling of their products.
Actavis CEO Brent Saunders has been the head of three different companies in less than two years, but with the $66bn acquisition of Allergan about to close any day now, he told Scrip that he's found the place where he plans to retire.
With the exit at the end of this month from the National Cancer Institute (NCI) of Dr Harold Varmus, who is stepping down as director after five years to open a research laboratory at Weill Cornell Medical College in New York and serve as an adviser to its dean, Dr Douglas Lowy, the agency's deputy director, will now take the reins as acting chief.